Analyst Sets Price Target for Abbott Laboratories (NYSE: ABT) Ahead of Earnings

Font: Financial Modeling Prep  • Oct 02, 2026

• An analyst has set a $127 price target for Abbott Laboratories (NYSE: ABT), suggesting significant upside potential for the healthcare stock.
• Despite recent stock declines, Abbott Laboratories anticipates robust quarterly earnings and strong revenue growth in its upcoming financial report.
• Abbott Laboratories is expanding its colorectal cancer screening portfolio with the introduction of the new SimpleScreen CRC blood test, enhancing its medical diagnostics offerings.

Abbott Laboratories (NYSE: ABT) is a leading healthcare company renowned for its diverse portfolio, including medical devices, diagnostic tests, medicines, and nutritional products. On October 2, 2026, Ed Ridley-Day of Redburn Partners set a $127 price target for the shares. This target represents a substantial 31.3% increase above their $96.71 price when the target was posted, offering a positive outlook for Abbott Laboratories stock.

This optimistic stock analysis follows a challenging month for Abbott Laboratories shares. As highlighted by Zacks, the shares closed at $98.83 on September 30, experiencing a 2.1% decline for the day, while the broader S&P 500 index fell by 0.25%. Over the past month, Abbott Laboratories shares saw a 7.33% decrease, contrasting with a 1.01% decline for the overall medical sector, indicating specific pressures on the company's stock performance.

Abbott Laboratories' next earnings report will provide crucial insights for investors to evaluate this price target against the company’s actual performance. Analysts project quarterly earnings of $1.43 per share, marking a strong 10% increase from the previous year. Furthermore, revenue growth is anticipated to reach $12.91 billion, an impressive 13.52% rise. Earnings per share (EPS), a key metric measuring profit divided by the number of shares, will be closely watched when Abbott Laboratories reports on October 21.

Beyond financial metrics, Abbott Laboratories is also expanding its significant colorectal cancer screening business. Its newly launched SimpleScreen CRC is an FDA-approved blood test designed for adults aged 45 and older at average risk. Abbott Laboratories estimates that up to 60 million Americans are currently due for screening. This innovative test joins Cologuard Plus, a stool-based option, further strengthening Abbott Laboratories' portfolio of medical diagnostics solutions.